Compare Core Scientific Inc (CORZ) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Core Scientific Inc vs Eli Lilly And Co — how do they compare? Core Scientific Inc trades at $15.5 (market cap $4.94B), while Eli Lilly And Co trades at $1,169.5 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 210.5× Core Scientific Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while Core Scientific Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Core Scientific Inc for 20 Days and Eli Lilly And Co for 93 Days on average.
| CORZ | LLY | |
|---|---|---|
Market Cap | $4.94B | $1.04T |
Volume | 15,630,800 | 3,064,878 |
Sector | Technology | Health |
52-Week High | $29.16 | $1.28K |
52-Week Low | $13.57 | $799.57 |
Typical Hold Time | 20 Days | 93 Days |
Enterprise Value | $7.46B | $1.09T |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CORZ trades at $15.94, down 4.44% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $288.62 million in 2025, with a negative net income margin of -324.9% in 2026. Recent news highlights its pivot to AI data center hosting and executive appointments, while analyst consensus remains strongly bullish with an 86.36% buy rating.
The outlook is mixed: strong analyst support and AI infrastructure growth offer upside potential, but persistent losses, high cash burn, and competitive pressures pose significant risks. Investors face volatility from execution challenges in the capital-intensive data center transition.
Eli Lilly (LLY) trades at $1,188.72, up 2.7% today, reflecting strong momentum driven by robust earnings beats and bullish technical signals. The stock exhibits impressive fundamentals with 2025 revenue of $65.18B and net income of $20.64B, yielding a net margin of 31.66%. Recent news highlights promising pipeline developments in weight-loss drugs, including EloraTZP, which outperformed Zepbound in trials, reinforcing its competitive edge in the obesity and diabetes markets.
Outlook remains positive given analyst consensus of a $1,350 price target and 73% buy ratings, though high valuation multiples (P/E 39.26) and rising debt-to-asset ratios (42.78% in 2024) warrant caution. Key risks include regulatory hurdles and intensifying competition from rivals like Novo Nordisk, but Lilly's innovation pipeline and market leadership position it for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Core Scientific Inc
Core Scientific provides digital infrastructure for Bitcoin mining and high-performance computing (HPC). It operates purpose-built data centers to support digital asset production and AI-related workloads.
Read more on CORZ →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
